T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems ...

(RTTNews) - T2 Biosystems, Inc. (TTOO) said it plans to commercialize the T2Lyme Panel in the third quarter of 2024 as a laboratory developed test without the need to be run on the T2Dx Instrument ...

A U.S. Army Combat Capabilities Development Command Armaments Center employee was recently recognized for leading a ...

LEXINGTON, Mass., November 3, 2015 - T2 Biosystems, Inc. (NASDAQ: TTOO), a company developing innovative diagnostic products to improve patient health, today announced the appointment of veteran ...

T2 Biosystems, Inc. has filed a registration statement for a Form S-1 (including a preliminary prospectus) with the Securities and Exchange Commission, or the SEC, for the public offering.

Finally, T2 Biosystems’ current distribution partner Biomedica, which secured the company’s second largest T2Dx Instrument contract in company history during 2023 in Poland, is re-entering the ...